Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid le... ecancer 4:36 2 years ago 542 Скачать Далее
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML VJHemOnc – Video Journal of Hematology & HemOnc 1:10 1 year ago 153 Скачать Далее
Asciminib and bosutinib efficacy in CML-CP patients: a comparison study VJHemOnc – Video Journal of Hematology & HemOnc 3:28 3 years ago 494 Скачать Далее
Phase I study of asciminib in patients with CP-CML carrying the T315I mutation VJHemOnc – Video Journal of Hematology & HemOnc 1:03 1 year ago 390 Скачать Далее
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia ecancer 6:40 3 years ago 732 Скачать Далее
Phase I study of olverembatinib in patients with R/R CML & Ph+ ALL VJHemOnc – Video Journal of Hematology & HemOnc 4:23 1 year ago 252 Скачать Далее
Asciminib has the potential to succeed where other TKIs have failed in CML VJHemOnc – Video Journal of Hematology & HemOnc 0:58 5 years ago 505 Скачать Далее
Safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients VJHemOnc – Video Journal of Hematology & HemOnc 1:35 7 years ago 361 Скачать Далее
Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia American Society of Hematology 5:37 3 years ago 1 199 Скачать Далее
Asciminib plus traditonal TKIs for chronic phase CML VJHemOnc – Video Journal of Hematology & HemOnc 3:08 5 years ago 615 Скачать Далее
FDA Approves Use of Asciminib for Philadelphia Chromosome Positive Chronic Myeloid Leukaemia MedSynapse 3:45 2 years ago 323 Скачать Далее
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates VJHemOnc – Video Journal of Hematology & HemOnc 1:24 1 year ago 258 Скачать Далее
ASC4KIDS: investigating asciminib for pediatric patients with CML VJHemOnc – Video Journal of Hematology & HemOnc 1:49 1 year ago 114 Скачать Далее
The BYOND trial: bosutinib shows promise in heavily pre-treated CML patients VJHemOnc – Video Journal of Hematology & HemOnc 2:04 3 years ago 229 Скачать Далее
Targeting TKI-resistant CML with LY3009120 and asciminib VJHemOnc – Video Journal of Hematology & HemOnc 2:40 2 years ago 362 Скачать Далее
The use of asciminib versus ponatinib for multiresistant CML VJHemOnc – Video Journal of Hematology & HemOnc 2:51 1 year ago 1 121 Скачать Далее
Update on ECOG-ACRIN EA9171: pembrolizumab + TKIs in patients with CML and persistent detectable MRD VJHemOnc – Video Journal of Hematology & HemOnc 2:13 2 years ago 121 Скачать Далее
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML VJHemOnc – Video Journal of Hematology & HemOnc 2:27 5 months ago 122 Скачать Далее
Managing drug resistance in CP-CML with ponatinib and asciminib VJHemOnc – Video Journal of Hematology & HemOnc 1:08 7 months ago 94 Скачать Далее
Asciminib: overcoming TKI resistance and reducing toxicity in CML VJHemOnc – Video Journal of Hematology & HemOnc 3:26 5 years ago 3 676 Скачать Далее
